Document Detail


Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer. GICOG (Gruppo Interregionale Cooperativo Oncologico Ginecologia), Italy.
MedLine Citation:
PMID:  1592277     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We report the long-term results of a randomized trial comparing cisplatin (P) with cisplatin and cyclophosphamide (CP) with cisplatin, cyclophosphamide, and adriamycin (CAP) in advanced ovarian cancer. Overall, this update confirms previously published data on 529 cases. Median survival times for the three treatments--CAP, CP, and P--are, respectively, 23, 20, and 19 months. The differences among the three arms are still nonsignificant and the estimated percentage survival at 7 years and confidence limits are, respectively, 21.7 (14.9-28.4), 17.0 (11.0-22.9), and 12.2 (6.9-17.4). According to the results of the Cox regression model on prognostic factors, higher grading, a larger residual tumor size, and performance status less than 80 (Karnovsky) all were independently associated with a poorer outcome, while a serous histotype was related to a better prognosis. The other variables (age, stage, center, type of surgery) initially included in the model did not appear to be significantly related to prognosis. The implications of these long-terms results relative to the application of combination chemotherapy with CAP or CP are discussed.
Authors:
-
Related Documents :
21364467 - Bone marrow aspirations and lumbar punctures in retinoblastoma at diagnosis: correlatio...
21345767 - Prognostic factors in patients with diffuse type gastric cancer (linitis plastica) afte...
21443137 - Neoadjuvant chemotherapy combining docetaxel, cisplatin and s-1 in gastric cancer with ...
14581337 - Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breas...
20154347 - Impact of number and site of lymph node invasion on survival of adenocarcinoma of esoph...
9865917 - Gamma-ray mutagen sensitivity and survival in patients with glioma.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Gynecologic oncology     Volume:  45     ISSN:  0090-8258     ISO Abbreviation:  Gynecol. Oncol.     Publication Date:  1992 May 
Date Detail:
Created Date:  1992-07-02     Completed Date:  1992-07-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0365304     Medline TA:  Gynecol Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  115-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cisplatin / administration & dosage,  therapeutic use*
Cohort Studies
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Female
Follow-Up Studies
Humans
Ovarian Neoplasms / drug therapy*,  metabolism
Peptichemio / administration & dosage
Regression Analysis
Time Factors
Chemical
Reg. No./Substance:
0/CAP protocol 2; 0/CP protocol; 15663-27-1/Cisplatin; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 9076-25-9/Peptichemio

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Oxidants and the pathophysiology of burn and smoke inhalation injury.
Next Document:  Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer.